Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB057643 Monotherapy or in Combination With Ruxolitinib in Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Feb 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of INCB-057643 in myelofibrosis (MF), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN) and 1 more (2 arms), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events at 9 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
INCB-057643
03
Conditions
myelofibrosis (MF)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04279847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279847.